The antibody discovery technology combines the power of proteomics to identify and clone antigen-specific monoclonal antibodies directly from the circulating serum of an immunized animal.
NG-XMT technology enables the isolation of monoclonal antibodies with antigen-specific activities, the company said.
CST chief scientific officer Roberto Polakiewicz said NG-XMT proteomics-based technology is faster and efficient than traditional hybridoma-based methods.
"Moreover, our proprietary and patent pending technology can be applied to the development of therapeutically relevant human monoclonal antibodies for vaccine development and for understanding basic questions in immunology," Polakiewicz added.